Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Fleming · SciRah

Researcher profile · Semantic Scholar

M. Fleming

Share profile

M. Fleming — researcher profile on SciRah

h-index: 27
Works: 82
Citations: 9,699

Most-cited papers

Increased survival with enzalutamide in prostate cancer after chemotherapy.
H. Scher, K. Fizazi, F. Saad, M. Taplin +16 more
2012New England Journal of Medicine4,425 citations Open access
Semantic Scholar
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial
J. Rosenberg, J. Hoffman-Censits, T. Powles, M. S. van der Heijden +27 more
2016The Lancet3,355 citations Open access
Semantic Scholar
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
J. de Bono, N. Mehra, G. Scagliotti, E. Castro +14 more
2021The Lancet Oncology237 citations Open access
Semantic Scholar
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
G. Sonpavde, V. Matveev, J. Burke, J. Caton +9 more
2012Annals of Oncology157 citations Open access
Semantic Scholar
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
G. Sonpavde, P. Periman, D. Bernold, D. Weckstein +7 more
2010Annals of Oncology124 citations Open access
Semantic Scholar
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
M. Galsky, Huan Wang, N. Hahn, P. Twardowski +21 more
2017European Urology112 citations
Semantic Scholar
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
N. Vogelzang, M. Olsen, J. McFarlane, E. Arrowsmith +21 more
2020Clinical Genitourinary Cancer85 citations Open access
Semantic Scholar
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
A. Siefker-Radtke, A. Necchi, S. Park, JesÃºs GarcÃa-Donas +14 more
201882 citations
Semantic Scholar
Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients
A. Hurria, M. Fleming, S. Baker, W. Kelly +11 more
2006Clinical Cancer Research71 citations Open access
Semantic Scholar
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
G. Sonpavde, A. Aparicio, F. Zhan, B. North +11 more
2011Urologic oncology67 citations
Semantic Scholar
Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer
D. Petrylak, P. Kantoff, N. Vogelzang, A. Mega +14 more
2019The Prostate66 citations
Semantic Scholar
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
M. Fleming, M. Morris, G. Heller, H. Scher
2006Nature Clinical Practice Oncology64 citations
Semantic Scholar
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
A. Armstrong, T. Shen, S. Halabi, G. Kemeny +8 more
2013Clinical Genitourinary Cancer63 citations
Semantic Scholar
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
M. Galsky, D. V. Von Hoff, M. Neubauer, T. Anderson +6 more
2012Investigational new drugs44 citations
Semantic Scholar
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
T. Powles, J. Gschwend, Y. Loriot, J. Bellmunt +14 more
201743 citations
Semantic Scholar
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
J. de Bono, M. Fleming, Judy S. Wang, R. Cathomas +12 more
2021Clinical Cancer Research42 citations
Semantic Scholar
A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC).
C. Hoimes, C. Albany, J. Hoffman-Censits, M. Fleming +15 more
2018Annals of Oncology41 citations Open access
Semantic Scholar
A Prospective Trial of Abiraterone Acetate Plus Prednisone in Black and White Men With Metastatic Castrate-Resistant Prostate Cancer
D. George, S. Halabi, E. Heath, A. Sartor +29 more
2021Cancer37 citations Open access
Semantic Scholar
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
M. Fleming, G. Sonpavde, M. Kolodziej, S. Awasthi +12 more
2012Clinical Genitourinary Cancer36 citations
Semantic Scholar
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
Tian Zhang, M. Harrison, P. O'Donnell, A. Alva +18 more
2020Cancer33 citations Open access
Semantic Scholar
Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).
D. George, E. Heath, A. Sartor, G. Sonpavde +17 more
2018Journal of Clinical Oncology33 citations
Semantic Scholar
Second-line chemotherapy for prostate cancer: patient characteristics and survival.
K. Beekman, M. Fleming, H. Scher, S. Slovin +3 more
2005Clinical Prostate Cancer33 citations
Semantic Scholar
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
Y. Loriot, A. Necchi, S. Park, J. García-Donas +14 more
201832 citations
Semantic Scholar
Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.
M. Galsky, N. Hahn, C. Albany, M. Fleming +10 more
201632 citations
Semantic Scholar
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
D. Petrylak, P. Kantoff, A. Mega, N. Vogelzang +6 more
2013Journal of Clinical Oncology29 citations
Semantic Scholar
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
M. Galsky, S. Pal, A. Mortazavi, M. Milowsky +16 more
2019Journal of Clinical Oncology28 citations
Semantic Scholar
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
M. Morris, D. Rathkopf, W. Novotny, J. Gibbons +5 more
2016Clinical Cancer Research27 citations Open access
Semantic Scholar
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
D. Petrylak, N. Vogelzang, G. Chatta, M. Fleming +16 more
201525 citations
Semantic Scholar
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
M. Galsky, K. Simon, G. Sonpavde, Thomas E. Hutson +3 more
2009Annals of Oncology23 citations Open access
Semantic Scholar
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.
N. Hahn, Beatrice S. Knudsen, S. Daneshmand, M. Koch +20 more
2016Urologic oncology20 citations
Semantic Scholar
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors
A. Tolcher, M. Mita, A. Patnaik, E. Rowinsky +6 more
200419 citations
Semantic Scholar
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
D. Westaby, Paul V. Viscuse, Rahul Ravilla, M. D. Fenor de la Maza +5 more
2021American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting17 citations
Semantic Scholar
A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
D. Petrylak, David C. Smith, L. Appleman, M. Fleming +10 more
201417 citations
Semantic Scholar
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
M. Taplin, A. Hussain, Satish Shah, N. Shore +16 more
2019Journal of Clinical Oncology16 citations
Semantic Scholar
21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
J. Rosenberg, D. Petrylak, O. Abidoye, M. S. van der Heijden +16 more
201515 citations
Semantic Scholar
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Shilpa Gupta, L. Nordquist, M. Fleming, W. Berry +5 more
2018Clinical Cancer Research13 citations Open access
Semantic Scholar
PD52-03 A MULTICENTER PHASE 1B/2 STUDY OF NEOADJUVANT PEMBROLIZUMAB AND CISPLATIN CHEMOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL CANCER
Hristos Z. Kaimakliotis, C. Albany, J. Hoffman-Censits, E. Trabulsi +15 more
2019Journal of Urology12 citations Open access
Semantic Scholar
Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.
M. Fleming, D. Rathkopf, J. Gibbons, A. Peterson +4 more
2013Journal of Clinical Oncology11 citations
Semantic Scholar
Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Ian D. Schnadig, M. Bhor, N. Vogelzang, D. Hennessy +8 more
2013Journal of Clinical Oncology11 citations
Semantic Scholar
PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).
K. Chi, M. Fleming, K. Sunderland, C. Albany +9 more
201710 citations
Semantic Scholar
HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC).
C. Hoimes, R. Abouassaly, J. Saltzman, M. Fleming +8 more
201610 citations
Semantic Scholar
PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
D. Petrylak, N. Vogelzang, K. Chatta, M. Fleming +17 more
2019The Prostate8 citations
Semantic Scholar
DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).
M. Galsky, A. Uzilov, R. McBride, Huan Wang +16 more
20178 citations
Semantic Scholar
Sequential Therapy in Metastatic Renal Cell Carcinoma
B. Hirsch, J. Burke, M. Agrawal, R. Hauke +4 more
2016Journal of Kidney Cancer and VHL8 citations Open access
Semantic Scholar
Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).
M. Galsky, N. Hahn, C. Albany, M. Fleming +10 more
20158 citations
Semantic Scholar
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations.
S. Pal, S. Daneshmand, S. Matin, Y. Loriot +12 more
2020Journal of Clinical Oncology7 citations
Semantic Scholar
KEYNOTE-361: Phase 3 trial of pembrolizumab ± chemotherapy versus chemotherapy alone in advanced urothelial cancer
T. Powles, Y. Loriot, J. Gschwend, J. Bellmunt +14 more
20187 citations
Semantic Scholar
244 Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
D. Petrylak, P. Kantoff, A. Mega, J. Stephenson +6 more
20124 citations
Semantic Scholar
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
S. Slovin, K. Knudsen, S. Halabi, R. de Leeuw +10 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC).
G. Sonpavde, V. Matveev, J. Burke, J. Caton +6 more
2011Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Sonpavde×15
Invite
G. Sonpavde — researcher profile on SciRah
M. Galsky×14
Invite
M. Galsky — researcher profile on SciRah
W. Berry×10
Invite
W. Berry — researcher profile on SciRah
N. Vogelzang×9
Invite
N. Vogelzang — researcher profile on SciRah

×8

Invite

N. Shore — researcher profile on SciRah

Invite

D. Petrylak — researcher profile on SciRah

Invite

Y. Loriot — researcher profile on SciRah

Invite

N. Hahn — researcher profile on SciRah

Invite

H. Scher — researcher profile on SciRah

Thomas E. Hutson×6

Invite

Thomas E. Hutson — researcher profile on SciRah

Invite

C. Albany — researcher profile on SciRah

Invite

R. Hauke — researcher profile on SciRah